Home > Resources > Whitepapers > Oxetanes in Drug Discovery

Oxetanes in Drug Discovery

July 10, 2019

Oxetanes have been employed to improve drugs’ physiochemical properties. Currently, over a dozen oxetane-containing drugs have progressed to different phases of clinical trials. Once one of them gains the FDA approval, the enthusiasm toward its utility in drug discovery will grow exponentially.

Spotlight

Acura Pharmaceuticals, Inc

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. Limitx™ Technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. In 2014, we were awarded a $300,000 grant from the National Institute on Drug Abuse to advance early stage development of our Limitx Technology.

OTHER WHITEPAPERS

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.